News GW Pharma tops list of UK R&D spenders Pharma is leading the way in R&D investment in the UK, with cannabis medicine specialist GW splurging almost 1,345% of its total revenue on research according to an analysis.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.